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Background: The diagnosis and treatment of indeterminate dominant strictures (DS) in patients with
primary sclerosing cholangitis (PSC) is challenging and the literature on the subject is scarce.
Objectives: This review aims to appraise and synthesize the evidence published in the English-language
medical literature on this topic.
Methods: Scientific papers published from 1950 until week 4 of July 2010 were extracted from
MEDLINE, Ovid Medline In-Process, the Cochrane Database of Systematic Reviews, the Database of
Systematic Reviews, the Database of Abstracts of Reviews of Effects, EMBASE, PubMed and the
National Library of Medicine Gateway.
Results: Strategies for the optimal management of DS in PSC patients are supported only by level II and
III evidence. Intraductal endoscopic ultrasound appears to be the most sensitive (64%) and specific (95%)
diagnostic test for the evaluation of DS in PSC. Endoscopic and percutaneous dilatations achieve 1- and
3-year palliation in 80% and 60% of patients, respectively. Although dilatation and stenting are the most
common palliative interventions in DS, no randomized trials on the optimal duration of treatment have
been conducted.
Conclusions: In benign DS, endoscopic dilatation with short-term stenting seems to be effective and
safe and does not increase the risks for malignant transformation or complications after liver transplan-
tation. Surgical bile duct resection and/or bilioenteric bypass are indicated only in patients with preserved
liver function.
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Introduction
Primary sclerosing cholangitis (PSC) is a progressive cholestatic
liver disease with patchy inflammatory fibrosis and strictures of
the intra- and extrahepatic bile ducts.1 The presence of T lym-
phocyte infiltrates in areas of severe inflammation2 would suggest
an autoimmune pathogenesis.3 Recent American and European
studies show the prevalence of PSC to be 20.9 per 100 000 men
and 6.3 per 100 000 women4 and the incidence to be 0.9–1.3 per
100 000 individuals per year.5,6
The diagnosis of PSC requires the exclusion of secondary causes
of sclerosing cholangitis, such as surgical trauma, presence of
intraductal stones or recurrent episodes of inflammation.7 The
management of early PSC is controversial and no therapy has
been proven to prolong survival except for orthotopic liver trans-
plantation (OLT).8 Ursodeoxycholic acid,8–12 corticosteroids,13–15
endoscopic or percutaneous dilatation of biliary strictures,16,17 and
drainage or surgical resection of isolated extrahepatic stenosis18–20
have been used to slow the progression of the disease, with limited
success.
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In 15–20% of patients with PSC, a localized high-grade stenosis
is the most prominent feature at the time of presentation.21,22
These dominant strictures (DS) can be located in the intrahepatic
ducts but, more frequently, they are extrahepatic.
The radiological characteristics of benign DS in patients with
PSC mimic those of cholangiocarcinoma and the limitations of
current diagnostic modalities make the differential diagnosis quite
difficult.
The management of patients with PSC and DS is challeng-
ing because treatments depend on the nature of the DS.
Cholestasis is the principal cause of morbidity; it causes
acute deterioration of liver function and should be addressed
promptly.23 Limited knowledge on how to differentiate benign
from malignant DS, on which treatment options are best and on
how to optimize symptoms of PSC while waiting for an OLT24
led us to perform a systematic review of the literature. The aim
of this review is to provide an evidence-based synthesis of
modern diagnostic strategies and management of DS in patients
affected by PSC.
Materials and methods
Evidence acquisition
Studies reporting epidemiology, diagnosis and therapy of DS
in patients affected by PSC were sought. Preference was given
to randomized controlled trials (RCTs) and prospective obser-
vational studies. MEDLINE, Ovid Medline In-Process, the
Cochrane Database of Systematic Reviews, the Database of
Systematic Reviews, the Database of Abstracts of Reviews of
Effects, EMBASE, PubMed and the National Library of Medicine
Gateway were searched using established systematic review
methods (Jadad Scale for Randomized Controlled Studies,
Downs and Black checklist for observational studies).25–27 In
addition, relevant general radiological, medical and surgical
journals were hand-searched, as were the reference lists of all
included articles for other relevant evidence and seminar and
conference abstracts. The reference search was limited to
English-language articles published from January 1950 until the
4th week of July 2010. Boolean logic methods were used to
combine medical subject heading terms (MeSH) used to identify
the articles referenced in this paper (Table 1). Two authors (MA
and MM) independently selected articles based on the content of
titles and abstracts. In cases of doubt, the article was reviewed in
its entirety. Decisions to include articles in this review were
reached by consensus.
Inclusion criteria
Studies on diagnostic tests were required to report at least one
of the following outcomes: sensitivity; specificity; positive and
negative predictive values, and accuracy.
Studies describing clinical outcomes were required to report
one or more of the following variables: success rate; failure rate;
morbidity or mortality; time to recurrence, and time to death or
liver transplantation.
Exclusion criteria
Articles published only as abstracts, papers in languages other
than English, studies on DS after liver transplantation, editorials,
letters, case reports describing fewer than 10 patients, reviews and
reports of in vitro or animal experiments were excluded.
In addition, as DS in patients with PSC is predominantly
managed by endoscopic or radiological interventions such as
stenting or dilatation or by surgical therapy, studies on medical
treatments were also excluded.
Definitions of terms
Definition of dominant strictures
Dominant strictures (DS) are discrete narrowings of the common
bile duct (CBD) or the common hepatic duct (CHD) that prevent
the normal flow of bile into the duodenum.28,29 In the current
literature, DS are defined as: (i) strictures of the CBD measuring
1.5 mm in diameter, or (ii) a diameter of the CHD measuring
1.0 mm within 2 cm of the bifurcation at the hilum.28,29
Figure 1 represents a schematic diagram of the main features of
DS in patients with PSC.
Definition of primary sclerosing cholangitis
The included papers defined PSC as a chronic and progressive
disease conditioning sclerosis of the biliary ducts. PSC was diag-
nosed on the basis of either liver biopsy or typical cholangio-
graphic findings in the presence of compatible biochemical
abnormalities and the absence of secondary causes of sclerosing
cholangitis.30
Definition of diagnostic modalities
Modalities used to diagnose PSC and DS included the full array
of imaging technologies, such as ultrasound (US), computed
tomography (CT), magnetic resonance imaging (MRI) and per-
cutaneous transhepatic cholangiography, endoscopic studies such
as endoscopic retrograde cholangiography (ERC) and cholangios-
copy, serological markers such as liver function tests and tumour
markers (e.g. CA19-9) and cytological and bioptic investigations.
Definition of interventions
Papers on treatments were divided into two groups based on the
nature of the interventions according to whether they described
non-surgical or surgical therapies. Non-surgical therapies were
defined as all interventions that did not require resection of the
biliary system (stenting or dilatation or both). All interventions
that required resection of the DS or liver transplantation were
defined as surgical.
Data extraction and quality control
The literature retrieval and the initial screening of relevant studies
were performed by MA and MM. Material was reviewed and
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coded as per the study protocol. Studies were scrutinized to
exclude any duplicate reports of the same group of patients. The
abstract of each article was appraised and if there was any sugges-
tion of relevant data, the full text was retrieved. Two doctors (MA
and MM) checked data from a random sample of studies for
reliability; discrepancies were resolved by consensus.
Aims of the study
The aims of this study were: (i) to report the epidemiology of
DS in patients affected by PSC; (ii) to assess the sensitivity and
specificity of imaging modalities, serum biomarkers, cytology and
histology in differentiating benign frommalignant DS, and (iii) to
assess the safety and effectiveness of non-invasive and invasive
therapies for DS.
Analysis
Statistical analysis was not possible as the data could not be
pooled because the variables of interest (e.g. diagnostic modali-
ties, medical interventions, endoscopic or radiology procedures,
surgical therapy) were frequently not available for all patients in
the same study. Furthermore, we observed significant heterogene-
ity in terms of the quality and design of the various studies, which
Table 1 Summary of all MeSH headings and terms used to identify publications on dominant strictures in patients affected by primary
sclerosing cholangitis in the MEDLINE, EMBASE and Cochrane Library databases
Primary MeSH terms Secondary MeSH terms
(epidemiology, diagnosis)
Secondary MeSH terms
(treatment, palliation)
Cholangitis
Sclerosing cholangitis
Primary sclerosing cholangitis
Biliary tract disease(s)
Bile duct disease(s)
Common bile duct
Bile duct(s)
Intrahepatic bile duct(s)
Extrahepatic bile duct(s)
Dominant or single or predominant
Stricture or stenosis or narrowing
Epidemiology
Classification
Diagnosis
Differential diagnosis
Early diagnosis
Risk factor(s)
Diagnostic imaging
MRI
Endosonography
Ultrasonography
Emission CT
Radionuclide imaging
PET
X-ray CT
Cytology
Cytodiagnosis
Tumour markers (biological)
Antigen(s)
Carcinoembryonic antigen
CA 19-9 antigen
ERCP
Cholangiography
In situ hybridization
Fluorescence in situ hybridization
Nucleic acid hybridization
Computer-assisted image processing
Resection
Therapeutic(s)
Treatment outcome(s)
Operation
Transplantation
Biliary tract surgical
Procedures liver
Organ transplantation
Clinical trial
Controlled clinical trial(s)
Random allocation
Randomized controlled trial(s)
Clinical trial (phase I)
Clinical trial (phase II)
Clinical trial (phase III)
Clinical trial (phase IV)
Drug therapy
Modality therapy
Drainage
Cholestasis
Obstructive jaundice
Pathology
Treatment outcome
Outcome assessment
Prognosis
Therapy
Boolean logic methods were used to combine MeSH headings and terms
MeSH, medical subject headings; MRI, magnetic resonance imaging; CT, computed tomography; PET, positron emission tomography; ERCP,
endoscopic retrograde cholangiopancreatography
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included, for example, retrospective or prospective observational
studies, semi-randomized trials and randomized trials.
Results
A total of 272 abstracts of studies published from 1950 through
2010 that appeared to meet the criteria for inclusion in this review
were identified. The selected studies were appraised and 94 were
approved for inclusion in this review according to the criteria
described earlier. The most common reasons for excluding studies
were that they reported outcomes of PSC patients with multiple
strictures or that they included patients with PSC and DS but did
not allow for the extrapolation of results of interest as themethods
described in the papers were not sufficiently clear. The studies
selected for the review did not include any RCTs as they were not
available; therefore only 76 retrospective observational studies and
18 prospective observational studies were included in this review.
Epidemiology
Dominant strictures of the extrahepatic bile ducts were observed
in 10–20% of patients with PSC.31–34 At the time of presentation,
approximately 75% of DS were benign, whereas 25% were malig-
nant.35 A large, prospective, cohort study of 159 Scandinavian
patients with a mean follow-up of 113 months (range: 3–345
months) showed that DS at the CBD were present in 23% of
participants. Dominant strictures were present in the right and
left hepatic ducts in 19% and 17% of cases, respectively.22 Overlap
among groups occurred frequently, as 12% of patients had mul-
tiple strictures.34
PSC was the most common risk factor for cholangiocarcinoma
in Western countries.36,37 The prevalence of cholangiocarcinoma
in patients with PSC ranged from 8% to 25%,35,37 with an annual
incidence of 1.2%.38 In a study investigating the natural history of
PSC, 62% of patients who developed cholangiocarcinoma had a
DS of the biliary tree.11 Furthermore, the presence of DS was an
independent factor for poor prognosis in patients who develop
cholangiocarcinoma.11 About 30% of cholangiocarcinomas in
patients with PSC occurred within 2 years of the diagnosis of
PSC10,39 and several findings seemed to be predictive for malignant
transformation, including: rapid clinical and biochemical deterio-
ration of liver function and presence of jaundice; pruritus; weight
loss; marked proximal ductal dilatation with progressive distal
strictures; elevated serum levels of CA 19-9 (>100 U/ml), and the
presence of dysplasia in bile duct brush cytology.40,41
Symptoms
In the early stage, DS were usually asymptomatic. As the disease
progressed, DS of extrahepatic bile ducts presented with an acute
exacerbation of jaundice, deterioration of liver function tests
and/or cholangitis.32,34 In a prospective study, enteric bacteria were
detected in the bile of 40% of patients affected by symptomatic
DS.42 Despite in vitro susceptibility, antibiotic treatment was not
Gallbladder 
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Stenosis of the common 
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Figure 1 Graphic representation of the intra- and extrahepatic biliary system. Dominant strictures are defined as stenosis of the common bile
duct with a diameter of 1.5 mm and/or stenosis of the hepatic duct with a diameter of 1.0 mm. The hepatic duct is the biliary tract distal
to the bifurcation of the right and left biliary systems and proximal to the cystic duct junction
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effective in eradicating bacteria from the bile ducts suggesting that
chronic bacterial infection may contribute to the progression of
the disease.42
Diagnostic modalities
Differentiation betweenmalignant and benign DS in patients with
PSC required the combination of several diagnostic modalities as
they complemented one another. Despite extensive investigations,
DS remained a very challenging condition to diagnose as each test
carried a risk for false negative or false positive results. Despite the
use of predictive criteria, differential diagnosis between a benign
DS and cholangiocarcinoma in PSC was challenging and most
cases of cholangiocarcinoma in PSC were detected at an advanced
stage and were unresectable; overall median survival was only 5
months.43
Laboratory tests
Table 2 summarizes the sensitivity, specificity, accuracy and
positive and negative predictive values of the most common
diagnostic laboratory tests.
Serum laboratory tests In the majority of patients affected by
DS and PSC, serum laboratory tests were neither sensitive nor
specific enough for either diagnosis or the evaluation of disease
progression.22,44 Often, patients had elevated levels of serum alka-
line phosphatase (ALP) and gamma-glutamyl transpeptidase
(GGT), and the serum total bilirubin level was elevated in only
about 40% of patients at presentation.6,7 Non-specific auto-
antibodies, such as antinuclear and antineutrophil cytoplasmic
immunoglobulins, were detected in 50–80% of patients45,46 and
elevated serum IgM levels were observed in only 45% of patients.45
Serum tumour markers A prospective study of 75 patients
affected by PSC evaluated the use of serial levels of four serum
tumour markers (CEA [carcinoembryonic antigen], CA 19-9, CA
50 and CA 242) for the diagnosis of cholangiocarcinoma in
the presence of DS.47 Over a period of 3 years, two patients (3%)
developed cholangiocarcinoma, but only one had elevated levels
of at least one of the serum tumour markers. Serum tumour
markers CEA, CA 19-9, CA 50 and CA 242 appeared to be of
limited value because of their low sensitivity and specificity. One
of the criticisms of this study was that the number of patients who
developed cholangiocarcinoma was too small to allow the drawing
of generalizable conclusions.
A second prospective observational study from Germany
included a cohort of 106patients treatedwith ursodeoxycholic acid
and biliary endoscopic dilatations of DS over amedian of 5 years.48
CA 19-9 was elevated (>100 ng/ml) in 23.5% of patients, but
cholangiocarcinoma developed in only three individuals (3%). In
14 of 25 patients with elevated CA 19-9 levels, DS were diagnosed
and treated by endoscopic dilatations. In 71.4% of the endoscopi-
cally treatedpatients,CA19-9 levels decreased followingdilatation.
In a prospective study from the Mayo Clinic,49 serum CA 19-9 was
evaluated in 86 patients with indeterminate DS. For the diagnosis
of cholangiocarcinoma, serum levels of CA 19-9100 ng/ml had
sensitivity, specificity, accuracy, and positive and negative predic-
tive values of 42%, 91%, 64%, 86% and 55%, respectively. In this
cohort, 36 patients hadbeenpreviously diagnosedwithPSC; in this
selected group, CA 19-9 100 ng/ml had sensitivity, specificity,
accuracy, and positive and negative predictive values of 14%, 95%,
61%,67%and60%,respectively.49At present,data from the current
literature suggest that an increased serum level of CA 19-9 in PSC
patients hasunsatisfactory sensitivity andpositive predictive values
for the diagnosis of cholangiocarcinoma.
Biliary tumour markers A prospective cohort of 34 patients
affected by benign DS due to ischaemia or chronic pancreatitis
underwent bile collection via transhepatic biliary drainage at the
Johns Hopkins Hospital.50 Bile levels of CEA were compared with
those in a group of 16 individuals at high risk for cholangiocar-
cinoma because they had choledochal cysts (n = 5), PSC with the
presence of DS (n = 6) or intrahepatic bile duct stones (n = 5).
Table 2 Summary of the sensitivity, specificity, accuracy and positive and negative predictive values of laboratory tests used to discriminate
between benign and malignant dominant strictures in patients with primary sclerosing cholangitis
Author(s) (year) Patients, n Diagnostic test Sensitivity Specificity Accuracy PPV NPV
Levy et al. (2008)49 36 Serum CA 19-9 100 ng/ml in 36 patients with
PSC among 86 patients enrolled in the study
14% 95% 61% 67% 60%
Nakeeb et al. (1996)50 34 Bile CEA >30 ng/ml in all patients with DS 72% 84% NA 72% 84%
Levy et al. (2008)49 86 Endoscopic luminal biopsy for all 86 patients
with DS enrolled in the study
29% 100% 71% 100% 67%
Levy et al. (2008)49 36 Brushings for 36 patients with PSC among 86
patients enrolled in the study
29% 100% 71% 100% 67%
Levy et al. (2008)49 36 FISH in 36 patients with PSC among 86 patients
enrolled in the study
64% 70% 68% 60% 74%
Levy et al. (2008)49 36 DIA in 36 patients with PSC among 86 patients
enrolled in the study
21% 95% 65% 75% 63%
PPV, positive predictive value; NPV, negative predictive value; NA, not available; PSC, primary sclerosing cholangitis; CEA, carcinoembryonic antigen;
DS, dominant strictures; FISH, fluorescence in situ hybridization; DIA, digital image analysis
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Levels of CEA in bile collected from individuals with benign
biliary strictures were significantly lower than in bile from patients
with histologically confirmed cholangiocarcinoma (10.1 
3.9 ng/ml vs. 50.2 5.8 ng/ml; P < 0.02). The majority of patients
with benign strictures secondary to pancreatitis, PSC, ischaemia
and stones had bile CEA levels of <30 ng/ml, whereas most
patients with cholangiocarcinoma had levels above this value. A
bile CEA level >30 ng/ml resulted in sensitivity of 72%, specificity
of 84%, a positive predictive value of 72% and a negative predic-
tive value of 84%.Although the measurement of CEA levels in the
bile of patients with PSC was promising, the test is only available
in selected medical centres and requires validation in a larger
population before it can be recommended as a diagnostic tool
for differentiation between benign and malignant DS.
Routine cytology In PSC patients, the majority of cases of
malignant DS presented in the perihilar region,51 which was acces-
sible for cytology sampling during ERC. In a prospective study of
61 PSC patients evaluated at the University of Oslo (Norway),
the sensitivity, specificity, accuracy, and positive and negative
predictive values of brush cytology were 100%, 84%, 88%, 68%
and 100%, respectively, for the combination of low- and high-
grade dysplasia/adenocarcinoma.52 When only patients with high-
grade dysplasia/adenocarcinoma were included, the sensitivity,
specificity, accuracy, and positive and negative predictive values of
the test decreased to 73%, 95%, 90%, 85% and 91%, respectively.52
In a more recent prospective study including 36 patients affected
by PSC and indeterminate DS,49 brush cytology had significantly
lower sensitivity (29%), excellent specificity (100%) and positive
predictive value (100%), and comparable accuracy (71%) and
negative predictive value (67%).
Endoscopic intraluminal biopsy Endoscopic intraluminal
biopsies are obtained from abnormal segments of the bile duct
using fluoroscopic guidance of regular bioptic forceps or during
cholangioscopy. In a recent prospective study of 86 patients
affected by DS,49 intraductal biopsies could not be obtained in
only seven individuals (8.1%). When these cases were excluded,
the sensitivity, specificity and accuracy of histology were 41%,
100% and 67%, respectively. Among the 86 patients enrolled in
this study, 34 (39%) were affected by PSC and intraluminal biopsy
provided histological samples with slightly lower sensitivity and
similar specificity, accuracy, and positive and negative predictive
values (29%, 100%, 71%, 100% and 67%, respectively).49
Fluorescence in situ hybridization Fluorescence in situ hybrid-
ization (FISH) utilizes fluorescent labelled DNA probes that bind
only to parts of chromosomes with a high degree of sequence
similarity and thus detects cells that have abnormalities indicative
of malignancy. In a prospective study, FISHwas used to investigate
the nature of cytological samples obtained from PSC patients with
indeterminate strictures.49 DNA probes used targeted centromeres
of chromosome 3 (CEP3), chromosome 7 (CEP7), chromosome
17 (CEP17) and band 9p21 (P16/CDKN2A gene). Two general
types of chromosomal abnormalities were observed by FISH:
polysomy and trisomy of chromosomes 7 or 3. In 36 patients
affected by PSC with cholangiocarcinoma, FISH was 64% sensi-
tive, 70% specific, 68% accurate and had positive and negative
predictive values of 60% and 74%, respectively.49
Digital image analysis Digital image analysis (DIA) is a form of
cytological analysis that requires spectrophotometry to quantify
cellular constituents.53 Small foci of tumour cells can be analysed54
by computer vision techniques and cell nuclei are classified as
diploid, aneuploid or tetraploid. Aneuploid and tetraploid speci-
mens are considered malignant.55 In a prospective study compar-
ing different modalities,49 DIA had overall sensitivity, specificity,
accuracy and positive and negative predictive values of 38%, 95%,
64%, 90% and 56%, respectively. Unfortunately, when DIA was
evaluated in 36 patients with PSC, its sensitivity, specificity, accu-
racy and positive and negative predictive values decreased to 21%,
95%, 65%, 75% and 63%, respectively.49
Non-invasive imaging modalities
Table 3 summarizes the sensitivity, specificity, accuracy and posi-
tive and negative predictive values of the non-invasive imaging
Table 3 Summary of the sensitivity, specificity, accuracy, positive and negative predictive values of non-invasive imaging modalities used to
discriminate between benign and malignant dominant strictures in patients with primary sclerosing cholangitis
Author(s) (year) Patients, n Diagnostic test Sensitivity Specificity Accuracy PPV NPV
Majoie et al. (1995)56 23 US (intrahepatic DS) 77% NA NA NA NA
Lee et al. (1995)57 85 US (extrahepatic DS) 94% NA NA NA NA
Macchi et al. (2004)59 16 CT cholangiography (extrahepatic DS) 94% NA NA NA NA
Eracleous et al. (2005)60 31 CT cholangiography (intrahepatic DS) 100% NA NA NA NA
Silverman et al. (1994)61 34 MRC 85% 92% NA 85% NA
Moff et al. (2006)62 36 MRC 85–91% 85–96% NA NA NA
Berstad et al. (2006)68 66 MRC 77–82% 81–93% 79–86% 86–94% 71–78%
PPV, positive predictive value; NPV, negative predictive value; NA, not available; US, ultrasound; DS, dominant strictures; CT, computed tomography;
MRC, magnetic resonance cholangiography
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modalities most commonly used to discriminate patients with
benign from malignant DS in the presence of PSC.
Ultrasonography Abdominal US seemed to be very sensitive in
detecting extrahepatic DS. In a prospective observational study
from the Netherlands, 23 consecutive patients with previously
established diagnoses of PSC underwent trans-abdominal US to
evaluate the intra- and extrahepatic biliary ducts.56 The major
limitation of US was its inability to exclude intrahepatic duct
disease: in 23% of patients the diagnosis of PSC was missed
but confirmed with ERC.56 By contrast, extrahepatic disease
was accurately diagnosed by US,57 that showed mural thickening
of the CBD, in 94% of patients and subsequently confirmed by
cholangiography.
Computerized tomography Technological advances in CT
scanning have improved the ability to evaluate the biliary system.
Recent reports have shown that CT cholangiography, defined as
CT scanning with i.v. administration of a contrast medium
selectively excreted in the biliary system, can be used to generate
three-dimensional images of the biliary tract.58 In a prospective
study carried out at the University of Padua (Italy),59 CT scan
findings were compared with magnetic resonance cholangiogra-
phy (MRC) images showing sensitivity values of 94% and 63% for
CT cholangiography and MRC, respectively. Extrahepatic disease
was diagnosed in 69% of patients using CT cholangiography in
comparison with 25% with magnetic resonance cholangiopancre-
atography (MRCP) (P < 0.05). These findings were confirmed by
a more recent retrospective study that showed that CT cholang-
iography provided better delineation of the biliary system in terms
of intrahepatic segmental strictures than MRC (100% vs. 80%,
respectively; P = 0.03).60
Magnetic resonance imaging Magnetic resonance cholangiog-
raphy has been extensively used for the diagnosis of PSC.59 In a
prospective case–control study of 34 patients, Silverman et al.
reported that MRC had sensitivity of 85–88%, specificity of
92–97% and positive predictive values of 85–94%.61 A recent ret-
rospective study comparing MRC with ERC in 36 patients showed
that extrahepatic and intrahepatic ductal visualization ofMRCwas
excellent in 64% and 66% of patients, respectively, compared with
86% and 74% for ERC.62 Sensitivity and specificity in MRC were
81–91%and 85–96%, respectively.Although the receiver operating
curve values were excellent for both MRC and ERC (0.9), interob-
server agreement was only good for identification of intrahepatic
stenosis (MRC, 0.64; ERC, 0.86) and only ERC achieved good
interobserver agreement for extrahepatic strictures (MRC, 0.36;
ERC, 0.55). Interobserver agreement was poor for both MRC and
ERC for the assessment of the degree of severity of PSC.62
Invasive diagnostic tests
Table 4 summarizes the sensitivity, specificity, accuracy and posi-
tive and negative predictive values of some of the invasive imaging
modalities commonly used to diagnose patients with DS and PSC.
Cholangiography In the majority of patients, the diagnosis of
DS was established with endoscopic retrograde cholangiopancre-
atography (ERCP) and less often with percutaneous transhepatic
cholangiography. Strictures were typically short and nearly all
patients had both intra- and extrahepatic duct involvement
(98.8%).63 Only in 20% of patients PSC involved only the intra-
hepatic and proximal extrahepatic ducts.63 ERC and percutaneous
transhepatic cholangiography provided high-quality images of
the biliary tract, but both were associated with risks for cholangi-
tis,64 haemorrhage65 and pancreatitis and bowel perforation.66 For
these reasons, MRC has become more popular for patients with
suspected PSC. In single-institution studies, ERC and MRC have
shown similar rates of sensitivity (82% and 80%, respectively),
and specificity (96% and 88%, respectively) for the diagnosing of
PSC. However, MRC demonstrated inferior performance in
detecting extrahepatic DS compared with ERC or CT cholangiog-
raphy.67,68
Transpapillary cholangioscopy In patients with DS and PSC,
non-invasive techniques had low sensitivity for detection of cho-
langiocarcinoma. Patients with DS should be referred for endo-
scopic brushing or biopsy to exclude cholangiocarcinoma as the
results of these tests influence clinical management and progno-
sis.52,69 In a well-designed, prospective, observational study from
Germany, 53 patients with PSC and DS underwent transpapillary
cholangioscopy and endoscopic tissue sampling in addition to
ERC.35 In comparison with ERC alone, cholangioscopy had higher
sensitivity (92% vs. 66%; P = 0.25), specificity (93% vs. 51%;
P < 0.001), accuracy (93% vs. 55%; P < 0.001), and positive
Table 4 Summary of the sensitivity, specificity, accuracy, positive and negative predictive values of invasive imaging modalities used to
discriminate between benign and malignant dominant strictures in patients with primary sclerosing cholangitis
Author(s) (year) Patients, n Diagnostic test Sensitivity Specificity Accuracy PPV NPV
Berstad et al. (2006)68 66 ERC 85–92% 78–81% 83–86% 86–87% 79–88%
Tischendorf et al. (2006)35 53 Transpapillary
cholangioscopy
92% 93% 93% 79% 97%
Levy et al. (2008)49 36 Intraductal US 64–71% 55–95% 62–82% 53–90% 73–79%
PPV, positive predictive value; NPV, negative predictive value; ERC, endoscopic retrograde cholangiography; US, ultrasound
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(79% vs. 29%; P < 0.001) and negative (97% vs. 84%; P < 0.001)
predictive values.
Intraductal ultrasound In a prospective study from the Mayo
Clinic, 86 patients were enrolled to assess the use of advanced
molecular and imaging techniques in the presence of indetermi-
nate DS.49 Intraductal ultrasound (IDUS) was performed by using
a 20-MHz US probe advanced over a guidewire at least 2 cm
proximal to the upper border of the stricture. The sensitivity,
specificity, accuracy, and positive and negative predictive values of
IDUS to detect cholangiocarcinoma in patients affected by PSC
(n = 36) were 71%, 55%, 62%, 53% and 73%, respectively. Except
for sensitivity, IDUS improved significantly in performance when
the operators used their clinical impressions rather than formal
criteria to diagnose cholangiocarcinoma as the sensitivity, speci-
ficity, accuracy and positive and negative predictive values of the
test changed to 64%, 95%, 82%, 90% and 79%, respectively.
Summary of findings for diagnostic modalities
In the majority of PSC patients, diagnosis of DS requires a
combination of non-invasive and invasive imaging modalities.
Although US has high sensitivity for extrahepatic DS, it is still
used only as a first-line modality for screening. Endoscopic retro-
grade cholangiography and MRC are the most commonly used
imaging modalities as they are relatively sensitive and specific. Of
the two, ERC is the more sensitive for extrahepatic DS and is
useful for obtaining cytology specimens and performing IDUS
and endoscopic intraluminal biopsies. However, ERC is disadvan-
taged by its invasive characteristics and the associated morbidity
and mortality and therefore has become a second-line modality
after MRC. Unfortunately, both MRC and ERC have relatively low
sensitivity and specificity for differentiating between benign and
malignant DS. During the last decade, several newmodalities have
been introduced for the diagnosis of cholangiocarcinoma in the
presence of DS. The use of molecular markers and imaging tech-
niques such as IDUS, FISH, DIA or a combination of multiple
modalities has enhanced diagnostic accuracy, achieving sensitivity
rates of up to 71% in the best series. However, no single test can be
considered as a reference standard for the differentiation of
benign from malignant DS. Combining several modalities with
the clinical characteristics of each patient is therefore necessary in
PSC patients.
Treatments
Orthotopic liver transplantation remains the only cure for
advanced PSC. Therefore, the most important considerations to
guide therapeutic decisions should refer to the impact that each
treatment might have on the feasibility of future OLT. As many
aspects must be considered, DS in PSC should be managed at
centres in which it is possible to take a multidisciplinary approach
to the problem. In the past, cases of DS were mainly managed
surgically, but, in view of the advances made in non-operative
modalities, management trends have shifted towards endoscopic
techniques as they are less invasive, can be performed in outpa-
tient settings and can be repeated whenever necessary.70
Primary sclerosing cholangitis is a slowly progressive disease
and patients survive for several years before requiring OLT. The
early management of DS is aimed at improving the symptoms and
quality of life of these patients without jeopardizing the possibility
of future OLT.
Minimally invasive procedures such as percutaneous or endo-
scopic dilatation with or without the use of stents have come to
represent first-line interventions. Resection or bypass surgery has
been performed only in a small and selected group of patients
with DS in the extrahepatic duct without signs of cirrhosis.71
Non-operative therapies
Endoscopic therapy Non-operative therapies have several
advantages: they have lower complication rates, can be performed
under sedation and can be repeated several times if necessary
without altering the biliary anatomy or compromising the possi-
bility of future OLT.
Endoscopic and percutaneous biliary dilatations in benign DS
could achieve clinical and biochemical response or improvement
in approximately 80% of non-cirrhotic patients.28,43,72–75 In the
majority of cases, more than one session of dilatation was neces-
sary to achieve the desired results.74,75 Stents were often used with
the aim of improving patency after dilatation. However, recent
studies have reported that biliary stents were associated with an
increased risk for cholangitis as a result of their occlusion over
time.74,75 Because of the small numbers of subjects, and the differ-
ences in stenting protocols, interpretation of the outcomes after
endoscopic therapy for DS in PSC patients was somewhat diffi-
cult. In a retrospective study of 63 patients, repeated endoscopic
dilatation (a mean of 2.3 times per patient) with concomitant
intake of ursodeoxycholic acid was associated with a 5-year sur-
vival of 83%, which was higher than predicted survival without
treatment.73 The deployment of temporary stents was necessary in
50% of patients following satisfactory dilatation of the DS. In a
prospective study of 106 patients with PSC treated with ursode-
oxycholic acid, Stiehl et al.74 performed interval ERCPs and docu-
mented the occurrence of benign DS in 52 patients (49%) who
subsequently underwent endoscopic dilatation. Common bile
duct stenoses were dilated up to a diameter of 24 French, whereas
stenoses of the intrahepatic ducts up to 2 cm proximal to the
bifurcation were dilated to a diameter of 18–24 French. Balloon
dilatations were repeated at 4-week intervals until satisfactory
dilatation was obtained. Only five individuals (10%) required
temporary stents and underwent a mean of 4.5 dilatations per
patient over 5 years. Similarly to the patients reported by Hazel
et al.,64 patients affected by DS had a 5-year survival of 70%,which
was higher than that predicted by the Mayo Clinic PSC survival
model.76
As these are observational studies, it was not possible to assess
whether ursodeoxycholic acid alone or its combination with
aggressive endoscopic therapy was responsible for the improved
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survival. One of the most important drawbacks of stent therapy
alone has been identified as the risk (up to 50%) for cholangitis
and sepsis associated with clogging of the stents.28 In a retrospec-
tive study of 32 PSC patients with symptomatic DS treated with
endoscopic stents for a mean of 11 days, short-term stenting was
used to avoid occlusion.28 When the stent was left in situ for only
1–2 weeks (median: 9 days), 81% of patients became asymptom-
atic and remained so without stent occlusions for a median
follow-up of 19 months.28 Improvements in clinical and bio-
chemical parameters were observed in 83% of patients, and 80%
and 60% of individuals remained free of re-intervention for 1 and
3 years, respectively. However, these studies did not examine the
effect of endoscopic stenting on survival or the eventual need for
OLT. A retrospective study compared two groups of PSC patients
with DS treated with balloon dilatation alone, and balloon dila-
tation plus stenting.77 Stent placement did not achieve additional
benefit after dilatation and was associated with further compli-
cations caused by infections.77 Randomized controlled trials are
necessary to determine whether stent therapy following dilatation
is superior to dilatation alone.
Percutaneous transhepatic therapies Percutaneous transhe-
patic dilatation and/or stenting produced clinical and biochemical
improvements similar to those brought about by endoscopic
therapy.78 This approach was usually used for symptomatic
patients in whom endoscopic management had failed because
percutaneous treatments have potential serious side-effects and
the discomfort caused by external stents decreases quality of life.
Surgical interventions
Liver transplantation Orthotopic liver transplantation is the
best treatment option for patients with PSC conditioning liver
failure. Overall 5-year survival rates in PSC patients treated by
OLT were 70–85%, and recurrence rates were 20–30% at 5
years.79,80 Although OLT provided the best survival for patients
with PSC, the number of grafts available was insufficient to match
the number of potential recipients.81 Therefore, OLT was per-
formed only when PSC was associated with liver failure.
Biliary resection or biliary bypass In PSC patients with DS but
without cirrhosis, the non-transplant surgical therapies available
included biliary resection or bypass with bilioenteric anastomo-
sis.73,82,83 Bypass procedures were technically less demanding than
bile duct resection and reconstruction, but they had the dis-
advantages of leaving the stricture of the bile duct in situ with the
potential for malignant transformation. Pitt et al. reported results
of bilioenterostomy in the form of hepaticojejunostomy, choledo-
chojejunostomy or choledochoduodenostomy in PSC patients
with DS of the extrahepatic bile ducts.83 The overall survival of the
22 patients managed with this approach was 82% with a median
follow-up of 5 years. In the same context, Myburgh reported an
actuarial survival of 100% with a median follow-up of 6.5 years in
16 non-cirrhotic PSC patients with DS managed with hepaticoje-
junostomy.82 Similar results were achieved by surgical resection.73
In a retrospective series from John Hopkins University, most PSC
patients with DS were managed surgically prior to 1990.20 The
authors of this study reported that 50 patients with DS of the
extrahepatic biliary tree secondary to PSC were treated with resec-
tion of the extrahepatic bile ducts and longterm transhepatic
stenting.20 This approach achieved an overall 5-year survival of
85% among non-cirrhotic patients.20 After 1990 the percentage of
patients who underwent biliary tract surgery at Johns Hopkins
Hospital decreased in favour of endoscopic therapy.20 Among 54
patients who underwent endoscopic or percutaneous dilatation
with or without stenting for DS, overall 5-year survival in non-
cirrhotic patients reached only 59%.20 Although survival in these
patients was inferior to that obtained by surgical resection,
procedure-related morbidity and mortality rates were higher
in patients who were treated surgically than in those treated
endoscopically.20
Several reports have reported that surgical therapy on the bile
system prior to OLT was associated with increased morbidity and
mortality at the time of transplant.84–87 Therefore, concerns have
been raised about the performance of any biliary tract operation
in patients who may need OLT.88–91 One study from Norway
reported that previous biliary surgery in PSC patients was associ-
ated with a higher rate of retransplantation.91 Generally, surgical
resection of DS in non-cirrhotic PSC patients should be strongly
considered for strictures that persist, recur soon after non-
operative therapy or are highly suspicious for malignancy.
Cirrhotic patients are best managed with OLT because non-
transplant surgical treatment in these patients was associated with
high operative mortality rates and poor longterm survival.73,82
Summary of findings for treatments
Orthotopic liver transplantation is the treatment of choice in
patients with PSC and cirrhosis. In this group of patients, endo-
scopic or percutaneous dilatationwith or without stenting provide
symptomatic relief and act as a bridge to organ replacement.
Symptomatic non-cirrhotic PSC patients with DS can be
treated both endoscopically and surgically. Repeated endoscopic
dilatations of DS improve survival over predicted survival without
treatment. Patients in whom non-operative techniques fail and
those in whom DS is suspicious for malignancy are best managed
by surgical therapy.
Although some studies have reported that treating DS in PSC
patients non-operatively is associated with an increased risk for
cholangiocarcinoma,92,93 others have failed to find any increased
risk for cholangiocarcinoma in patients undergoing endoscopic
therapy.73,94 Currently, there is insufficient evidence to suggest that
manipulation of the biliary systemwith interval dilatations and/or
stenting is associated with increased risk for cholangiocarcinoma.
There are no RCTs on the short- and longterm outcomes of
endoscopic vs. surgical therapy in PSC patients affected by symp-
tomatic DS. In addition, no prospective studies have compared the
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optimal duration of stent therapy and the frequency of endo-
scopic dilatation of DS.
Over the last decades, the use of multidisciplinary approaches
in PSC patients has improved their survival. Nevertheless, the
management of indeterminate DS remains a clinical challenge as
there is no strong evidence to guide clinicians in their decisions.
Controlled studies are needed to determine which therapeutic
options are most beneficial. Because the incidence of DS in PSC
patients who are not in need of OLT is low, such studies should be
performed in multicentre contexts.
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